Literature DB >> 29116254

Kidney cancer: PHGDH is key for targeting HIF in RCC.

Annette Fenner.   

Abstract

Entities:  

Year:  2017        PMID： 29116254     DOI： 10.1038/nrurol.2017.176

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.

Authors:  Hirofumi Yoshino; Nijiro Nohata; Kazutaka Miyamoto; Masaya Yonemori; Takashi Sakaguchi; Satoshi Sugita; Toshihiko Itesako; Satoshi Kofuji; Masayuki Nakagawa; Rajvir Dahiya; Hideki Enokida
Journal:  Cancer Res       Date:  2017-09-26       Impact factor: 12.701
  1 in total
  2 in total

Review 1.  3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.

Authors:  Mingxue Li; Canrong Wu; Yueying Yang; Mengzhu Zheng; Silin Yu; Jinhui Wang; Lixia Chen; Hua Li
Journal:  Cell Oncol (Dordr)       Date:  2021-03-18       Impact factor: 6.730

2.  PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/β-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib.

Authors:  Xiaocui Zhang; Meige Sun; Yisheng Jiao; Bei Lin; Qing Yang
Journal:  Oxid Med Cell Longev       Date:  2022-09-05       Impact factor: 7.310
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.